Plasma Protease C1-inhibitor Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Plasma Protease C1-inhibitor Market is Segmented by Drug, Dosage Form (Lyophilized and Injectable), and Geography

Plasma Protease C1-inhibitor Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Plasma Protease C1-Inhibitor Market Size

CAGR
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 6.90 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Plasma Protease C1-inhibitor Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Plasma Protease C1-inhibitor Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Plasma Protease C1-Inhibitor Market Analysis

The Plasma Protease C1-inhibitor Market is expected to register a CAGR of 6.9% during the forecast period.

The Plasma Protease C1-inhibitor Treatment Market is expected to experience a significant growth over the forecast period due to the growing incidence of hereditary angioedema (HAE). Hereditary angioedema is a potentially life-threatening genetic condition with incidence between 1 in 10,000 and 1 in 50,000 people according to HAE International (HAEi), the global umbrella organization for the world's HAE patient groups.

Additionally, increasing R&D investments, discovery of inhibitor drugs, increasing product approvals promising pipeline drugs and novel therapies for the treatment of hereditary angioedema are the few other factors driving the market globally.

Plasma Protease C1-Inhibitor Industry Overview

In Plasma Protease C1-inhibitor market, major players are focusing on various market strategies such as high research and development activities, partnerships, collaborations, acquisitions and mergers etc. Major players in the Plasma Protease C1-inhibitor market are CSL Behring LLC., Takeda Pharmaceutical Company Limited, Pharming Technologies B.V., KalVista Pharmaceuticals, Inc amongst others.

Plasma Protease C1-Inhibitor Market Leaders

  1. CSL Behring LLC

  2. Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)

  3. Pharming Technologies B.V.

  4. KalVista Pharmaceuticals, Inc.

  5. BioCryst Pharmaceuticals

  6. *Disclaimer: Major Players sorted in no particular order
Picture1Plasma Protease C1-inhibitor Market
Need More Details on Market Players and Competiters?
Download PDF

Plasma Protease C1-Inhibitor Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Hereditary Angioedema (HAE)
    • 4.2.2 Increasing Investments in the Research & Development Activities
  • 4.3 Market Restraints
    • 4.3.1 High Price of Esoteric Testing Procedures Restricting Market Entry
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 By Drug Type
    • 5.1.1 C1-inhibitors
    • 5.1.2 Kallikrein Inhibitor
    • 5.1.3 Selective Bradykinin B2 Receptor Antagonist
  • 5.2 By Dosage Form
    • 5.2.1 Lyphophlised
    • 5.2.2 Injectables
  • 5.3 Geography
    • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
    • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE

  • 6.1 CSL Limited (CSL Behring LLC)
  • 6.2 Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
  • 6.3 Ionis Pharmaceuticals, Inc.
  • 6.4 Pharming Technologies B.V.
  • 6.5 Centogene AG
  • 6.6 BioCryst Pharmaceuticals
  • 6.7 KalVista Pharmaceuticals, Inc.
  • 6.8 Fresenius Kabi

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Plasma Protease C1-Inhibitor Industry Segmentation

As per the scope of the report, plasma protease C1 inhibitor (C1 Inh) is a member of the serpin family of protease inhibitors and related proteins, and its mechanism of action is identical to those of the other protease inhibitor members of the family. SERPING1 forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases which will play a vital role in the regulation of blood coagulation, complement activation, generation of kinins and fibrinolysis. It is also an efficient FXIIa inhibitor. Mutations of the SERPING1 gene is associated with the adult macular degeneration which causes Hereditary Angioedema (HAE).

By Drug Type C1-inhibitors
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
By Dosage Form Lyphophlised
Injectables
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Plasma Protease C1-Inhibitor Market Research FAQs

What is the current Plasma Protease C1-inhibitor Market size?

The Plasma Protease C1-inhibitor Market is projected to register a CAGR of 6.9% during the forecast period (2025-2030)

Who are the key players in Plasma Protease C1-inhibitor Market?

CSL Behring LLC, Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings), Pharming Technologies B.V., KalVista Pharmaceuticals, Inc. and BioCryst Pharmaceuticals are the major companies operating in the Plasma Protease C1-inhibitor Market.

Which is the fastest growing region in Plasma Protease C1-inhibitor Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Plasma Protease C1-inhibitor Market?

In 2025, the North America accounts for the largest market share in Plasma Protease C1-inhibitor Market.

What years does this Plasma Protease C1-inhibitor Market cover?

The report covers the Plasma Protease C1-inhibitor Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Plasma Protease C1-inhibitor Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Plasma Protease C1-inhibitor Industry Report

Statistics for the 2025 Plasma Protease C1-inhibitor market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Plasma Protease C1-inhibitor analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.